Class Action Lawsuit Announced for Boston Scientific Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2026
0mins
Should l Buy BSX?
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Boston Scientific (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, with a deadline of May 4, 2026, for those wishing to serve as lead plaintiff, indicating the legal proceedings are underway.
- Potential Compensation Opportunity: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, which reduces the financial burden on affected shareholders and encourages broader participation in the lawsuit.
- Impact of Misleading Statements: The lawsuit alleges that Boston Scientific made materially false and misleading statements during the class period, leading to investor losses when the company missed net income expectations and provided underwhelming guidance for the first half of 2026, reflecting management's misleading confidence in the electrophysiology segment's growth.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.790
Low
94.00
Averages
108.14
High
132.00
Current: 69.790
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific Corporation (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment for class action participation.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management made overly positive statements while concealing the unsustainable growth rate of its U.S. EP segment, which misled investors and analysts, ultimately resulting in a significant net income miss.
- Dramatic Stock Decline: Following the disappointing fourth-quarter results and guidance issued on February 4, 2026, Boston Scientific's stock plummeted from $91.62 per share to $75.50, marking a 17.6% drop in just one day, indicating severe market disappointment regarding the company's outlook.
- Steps for Legal Participation: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress, ensuring they remain informed and can pursue potential recovery of losses.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Advice: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, particularly for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, aiming to safeguard investor rights.
- Investor Contact Information: Investors who have suffered losses are encouraged by securities litigation partner Josh Wilson to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss available legal options.
- Class Action Deadline: The firm reminds investors that May 4, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against Boston Scientific, emphasizing the importance of timely action.
- Company Background: Boston Scientific Corporation (NYSE:BSX) is a well-known medical device manufacturer, and the legal issues it faces could negatively impact its stock price and investor confidence, prompting investors to stay informed about developments to protect their interests.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's Q4 2025 results, released on February 4, 2026, revealed disappointing U.S. electrophysiology sales, leading to a 17.6% drop in stock price to $75.50 per share, causing significant investor losses.
- Poor Market Performance: The company acknowledged slower market growth and increased competition in its report, despite prior claims of strong growth in the electrophysiology segment, indicating a major misjudgment that undermined investor confidence.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose the unsustainable growth rate of its electrophysiology segment and the emergence of new competitors, which limited growth potential.
- Investor Action Required: Investors must file a lead plaintiff motion by May 4, 2026, to pursue claims for losses incurred due to the company's misleading statements, highlighting the urgency and significance of legal action.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Boston Scientific and certain officers, seeking damages for investors who purchased securities between July 23, 2025, and February 3, 2026, highlighting significant investor concerns regarding financial transparency.
- False Statement Allegations: The complaint alleges that Boston Scientific made materially false and misleading statements during the relevant period, particularly regarding the sustainability of growth in its U.S. electrophysiology segment, revealing vulnerabilities under competitive and regulatory pressures that could undermine investor confidence.
- Growth Expectation Missteps: The lawsuit indicates that management's confidence in the U.S. electrophysiology division lacked a reasonable basis and failed to disclose adverse trends affecting procedure volumes and increasing competition, potentially impacting future revenue forecasts and exacerbating investor loss risks.
- Investor Action Call: Boston Scientific investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, demonstrating a proactive and urgent approach to safeguarding their rights amidst the allegations.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific Corporation (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment for class action participation.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management made overly positive statements while concealing the unsustainable growth rate of its U.S. EP segment, which misled investors and analysts, ultimately resulting in a significant net income miss.
- Dramatic Stock Decline: Following the disappointing fourth-quarter results and guidance issued on February 4, 2026, Boston Scientific's stock plummeted from $91.62 per share to $75.50, marking a 17.6% drop in just one day, indicating severe market disappointment regarding the company's outlook.
- Steps for Legal Participation: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress, ensuring they remain informed and can pursue potential recovery of losses.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Advice: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, particularly for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, aiming to safeguard investor rights.
- Investor Contact Information: Investors who have suffered losses are encouraged by securities litigation partner Josh Wilson to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss available legal options.
- Class Action Deadline: The firm reminds investors that May 4, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against Boston Scientific, emphasizing the importance of timely action.
- Company Background: Boston Scientific Corporation (NYSE:BSX) is a well-known medical device manufacturer, and the legal issues it faces could negatively impact its stock price and investor confidence, prompting investors to stay informed about developments to protect their interests.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's Q4 2025 results, released on February 4, 2026, revealed disappointing U.S. electrophysiology sales, leading to a 17.6% drop in stock price to $75.50 per share, causing significant investor losses.
- Poor Market Performance: The company acknowledged slower market growth and increased competition in its report, despite prior claims of strong growth in the electrophysiology segment, indicating a major misjudgment that undermined investor confidence.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose the unsustainable growth rate of its electrophysiology segment and the emergence of new competitors, which limited growth potential.
- Investor Action Required: Investors must file a lead plaintiff motion by May 4, 2026, to pursue claims for losses incurred due to the company's misleading statements, highlighting the urgency and significance of legal action.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Boston Scientific and certain officers, seeking damages for investors who purchased securities between July 23, 2025, and February 3, 2026, highlighting significant investor concerns regarding financial transparency.
- False Statement Allegations: The complaint alleges that Boston Scientific made materially false and misleading statements during the relevant period, particularly regarding the sustainability of growth in its U.S. electrophysiology segment, revealing vulnerabilities under competitive and regulatory pressures that could undermine investor confidence.
- Growth Expectation Missteps: The lawsuit indicates that management's confidence in the U.S. electrophysiology division lacked a reasonable basis and failed to disclose adverse trends affecting procedure volumes and increasing competition, potentially impacting future revenue forecasts and exacerbating investor loss risks.
- Investor Action Call: Boston Scientific investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, demonstrating a proactive and urgent approach to safeguarding their rights amidst the allegations.
See More
